Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy.

By D. Cardinale, A. Colombo, Giuseppina Lamantia, N. Colombo, M. Civelli, G. de Giacomi, M. Rubino, F. Veglia, C. Fiorentini, C. Cipolla. Journal of the American College of Cardiology, 2010

1,097 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Oncology

View Paper: https://www.semanticscholar.org/paper/b9778cf6fd2564f78da822ff42f2cacfa1d3b1ae

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

In Oncology

J. Herrmann

Citations in the corpus

Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. (2014, background): “A further study demonstrated the role and limitations of an LVEF decrease initiating cardiac treatment in chemotherapy patients.(143) In 201 consecutive patients with LV dysfunction (LVEF < 45%) due to anthracycline cardiomyopathy,(143) enalapril (and, if possible, carvedilol) were initiated promptl”
Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy (2015, neutral): “001 Chest-wall RT (left),* n (%) 49 (27) 392 (16) 0.”
Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. (2014, background): “They found that LVEF recovery was more likely with early initiation of an ACE inhibitor and beta-blocker after completion of anthracycline treatment (63).”
Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. (2012, positive): “Recent findings reported in a large population of anthracycline-induced CMP patients demonstrated that the time elapsed from the end of chemotherapy to the start of HF therapy (time-to-treatment), with ACE-I and, when tolerated, with BB, is a crucial variable for recovery of cardiac dysfunction [29,”
Myocardial strain imaging: how useful is it in clinical decision making? (2015, background): “When reduction in LVEF during chemotherapy is established, it may be too late for treatment.(41) Importantly, reduction in myocardial strain precede significant change in LVEF.”
Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. (2014, background): “A further study demonstrated the role and limitations of an LVEF decrease initiating cardiac treatment in chemotherapy patients.(143) In 201 consecutive”
Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management (2016, methodology): “In 201 consecutive patients with anthracycline-induced LVD, enalapril (combined with carvedilol when possible) was initiated at the time of LVEF impairment detection and was up-titrated to the maximal tolerated dose.(63) The investigators found that the time elapsed from the end of chemotherapy to t”
Anthracycline Cardiotoxicity: Prevalence, Pathogenesis and Treatment (2011, background): “These responders had a higher LVEF after the onset of congestive heart failure compared to partial responders (those whose LVEF increased >10% but did not normalize) and nonresponders and had therapy initiated sooner than partial responders and nonresponders [79].”
Anthracycline Chemotherapy and Cardiotoxicity (2017, background): “Prompt initiation of ACE inhibitors and β-blockers when LVEF declines is important for recovery of function [71, 95].”
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). (2016, methodology): “In general, the cardiovascular concerns can be summarized in categories related to myocardial dysfunction, vascular disease and VHD. 4.1 Myocardial dysfunction Both paediatric and adult survivors of anthracycline-based chemotherapy have a lifelong risk for the development of LV dysfunction and HF.10”